Intrinsic value of Cytokinetics, Incorporated - CYTK

Previous Close

$10.73

  Intrinsic Value

$0.10

stock screener

  Rating & Target

str. sell

-99%

Previous close

$10.73

 
Intrinsic value

$0.10

 
Up/down potential

-99%

 
Rating

str. sell

We calculate the intrinsic value of CYTK stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  33
  33
  34
  35
  36
  37
  39
  40
  42
  43
  45
  47
  49
  51
  53
  55
  58
  60
  63
  66
  69
  72
  76
  79
  83
  87
  91
  95
  100
  105
Variable operating expenses, $m
  309
  316
  324
  333
  343
  355
  367
  380
  394
  409
  425
  442
  460
  480
  501
  522
  546
  570
  596
  624
  652
  683
  715
  749
  785
  822
  862
  903
  947
  993
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  309
  316
  324
  333
  343
  355
  367
  380
  394
  409
  425
  442
  460
  480
  501
  522
  546
  570
  596
  624
  652
  683
  715
  749
  785
  822
  862
  903
  947
  993
Operating income, $m
  -276
  -283
  -290
  -298
  -307
  -317
  -328
  -340
  -352
  -366
  -380
  -395
  -412
  -429
  -448
  -467
  -488
  -510
  -533
  -558
  -583
  -611
  -639
  -670
  -702
  -735
  -771
  -808
  -847
  -888
EBITDA, $m
  -275
  -282
  -289
  -297
  -306
  -316
  -327
  -338
  -351
  -364
  -379
  -394
  -411
  -428
  -446
  -466
  -487
  -509
  -532
  -556
  -582
  -609
  -638
  -668
  -700
  -733
  -769
  -806
  -845
  -886
Interest expense (income), $m
  2
  4
  -11
  -11
  -11
  -11
  -11
  -11
  -11
  -11
  -10
  -10
  -10
  -10
  -10
  -10
  -9
  -9
  -9
  -9
  -9
  -8
  -8
  -8
  -7
  -7
  -7
  -6
  -6
  -6
  -5
Earnings before tax, $m
  -281
  -271
  -279
  -287
  -296
  -306
  -317
  -329
  -342
  -355
  -369
  -385
  -402
  -419
  -438
  -458
  -479
  -501
  -524
  -549
  -575
  -603
  -632
  -662
  -695
  -729
  -764
  -802
  -841
  -883
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -281
  -271
  -279
  -287
  -296
  -306
  -317
  -329
  -342
  -355
  -369
  -385
  -402
  -419
  -438
  -458
  -479
  -501
  -524
  -549
  -575
  -603
  -632
  -662
  -695
  -729
  -764
  -802
  -841
  -883

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  33
  33
  34
  35
  36
  37
  39
  40
  42
  43
  45
  47
  49
  51
  53
  55
  58
  60
  63
  66
  69
  72
  76
  79
  83
  87
  91
  96
  100
  105
Adjusted assets (=assets-cash), $m
  33
  33
  34
  35
  36
  37
  39
  40
  42
  43
  45
  47
  49
  51
  53
  55
  58
  60
  63
  66
  69
  72
  76
  79
  83
  87
  91
  96
  100
  105
Revenue / Adjusted assets
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  0.990
  1.000
  1.000
Average production assets, $m
  3
  4
  4
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
  10
  10
  11
  11
Working capital, $m
  -11
  -11
  -11
  -12
  -12
  -12
  -13
  -13
  -14
  -14
  -15
  -16
  -16
  -17
  -18
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -28
  -29
  -30
  -32
  -33
  -35
Total debt, $m
  -111
  -110
  -109
  -109
  -108
  -106
  -105
  -104
  -103
  -101
  -100
  -98
  -96
  -95
  -93
  -90
  -88
  -86
  -83
  -81
  -78
  -75
  -72
  -69
  -66
  -62
  -58
  -54
  -50
  -46
Total liabilities, $m
  29
  30
  31
  32
  33
  34
  35
  36
  37
  39
  40
  42
  44
  46
  48
  50
  52
  54
  57
  59
  62
  65
  68
  71
  75
  78
  82
  86
  90
  95
Total equity, $m
  3
  3
  3
  4
  4
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
  10
  10
  11
Total liabilities and equity, $m
  32
  33
  34
  36
  37
  38
  39
  40
  41
  43
  44
  47
  49
  51
  53
  56
  58
  60
  63
  66
  69
  72
  76
  79
  83
  87
  91
  96
  100
  106
Debt-to-equity ratio
  -33.920
  -32.950
  -31.900
  -30.780
  -29.610
  -28.400
  -27.170
  -25.930
  -24.680
  -23.430
  -22.200
  -20.980
  -19.790
  -18.620
  -17.480
  -16.360
  -15.280
  -14.240
  -13.230
  -12.250
  -11.310
  -10.400
  -9.530
  -8.690
  -7.890
  -7.120
  -6.380
  -5.670
  -4.990
  -4.350
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -281
  -271
  -279
  -287
  -296
  -306
  -317
  -329
  -342
  -355
  -369
  -385
  -402
  -419
  -438
  -458
  -479
  -501
  -524
  -549
  -575
  -603
  -632
  -662
  -695
  -729
  -764
  -802
  -841
  -883
Depreciation, amort., depletion, $m
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
Funds from operations, $m
  -280
  -270
  -278
  -286
  -295
  -305
  -316
  -328
  -340
  -354
  -369
  -384
  -401
  -418
  -437
  -457
  -478
  -500
  -523
  -548
  -574
  -601
  -630
  -661
  -693
  -727
  -762
  -800
  -839
  -881
Change in working capital, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
Cash from operations, $m
  -280
  -270
  -277
  -286
  -295
  -305
  -316
  -327
  -340
  -353
  -368
  -383
  -400
  -418
  -436
  -456
  -477
  -499
  -522
  -547
  -573
  -600
  -629
  -660
  -692
  -725
  -761
  -798
  -838
  -879
Maintenance CAPEX, $m
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
New CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
Cash from investing activities, $m
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
Free cash flow, $m
  -280
  -271
  -278
  -286
  -296
  -306
  -316
  -328
  -341
  -355
  -369
  -385
  -401
  -419
  -437
  -457
  -478
  -500
  -524
  -548
  -574
  -602
  -631
  -662
  -694
  -728
  -763
  -801
  -840
  -882
Issuance/(repayment) of debt, $m
  -153
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
Issuance/(repurchase) of shares, $m
  435
  272
  279
  287
  296
  306
  317
  329
  342
  355
  370
  385
  402
  419
  438
  458
  479
  501
  525
  549
  576
  603
  632
  663
  695
  729
  765
  802
  842
  883
Cash from financing (excl. dividends), $m  
  282
  273
  280
  288
  297
  307
  318
  330
  343
  356
  372
  387
  404
  421
  440
  460
  481
  503
  527
  552
  579
  606
  635
  666
  698
  733
  769
  806
  846
  887
Total cash flow (excl. dividends), $m
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
Retained Cash Flow (-), $m
  -435
  -272
  -279
  -287
  -296
  -306
  -317
  -329
  -342
  -355
  -370
  -385
  -402
  -419
  -438
  -458
  -479
  -501
  -525
  -549
  -576
  -603
  -632
  -663
  -695
  -729
  -765
  -802
  -842
  -883
Prev. year cash balance distribution, $m
  177
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -257
  -270
  -278
  -286
  -295
  -305
  -315
  -327
  -340
  -353
  -368
  -383
  -399
  -417
  -435
  -455
  -476
  -498
  -521
  -546
  -572
  -599
  -628
  -658
  -690
  -724
  -759
  -797
  -836
  -877
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -246
  -247
  -242
  -235
  -228
  -221
  -213
  -204
  -195
  -185
  -175
  -163
  -152
  -140
  -128
  -116
  -104
  -92
  -80
  -69
  -59
  -50
  -41
  -34
  -27
  -21
  -16
  -12
  -9
  -7
Current shareholders' claim on cash, %
  50.0
  5.4
  0.6
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

FINANCIAL RATIOS  of  Cytokinetics, Incorporated (CYTK)

Valuation Ratios
P/E Ratio 27.3
Price to Sales 4.1
Price to Book 4.6
Price to Tangible Book
Price to Cash Flow 11.8
Price to Free Cash Flow 12.5
Growth Rates
Sales Growth Rate 265.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 100%
Cap. Spend. - 3 Yr. Gr. Rate 14.9%
Financial Strength
Quick Ratio 52
Current Ratio 0
LT Debt to Equity 28.7%
Total Debt to Equity 31.9%
Interest Coverage 9
Management Effectiveness
Return On Assets 12.6%
Ret/ On Assets - 3 Yr. Avg. -10.6%
Return On Total Capital 15.4%
Ret/ On T. Cap. - 3 Yr. Avg. -16.1%
Return On Equity 19.6%
Return On Equity - 3 Yr. Avg. -16%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 17.9%
EBITDA Margin - 3 Yr. Avg. -47.2%
Operating Margin 17%
Oper. Margin - 3 Yr. Avg. -47.5%
Pre-Tax Margin 15.1%
Pre-Tax Margin - 3 Yr. Avg. -49.3%
Net Profit Margin 15.1%
Net Profit Margin - 3 Yr. Avg. -49.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CYTK stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CYTK stock intrinsic value calculation we used $32 million for the last fiscal year's total revenue generated by Cytokinetics, Incorporated. The default revenue input number comes from 0001 income statement of Cytokinetics, Incorporated. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CYTK stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CYTK is calculated based on our internal credit rating of Cytokinetics, Incorporated, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Cytokinetics, Incorporated.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CYTK stock the variable cost ratio is equal to 946.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CYTK stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 10.2% for Cytokinetics, Incorporated.

Corporate tax rate of 27% is the nominal tax rate for Cytokinetics, Incorporated. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CYTK stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CYTK are equal to 10.6%.

Life of production assets of 2.7 years is the average useful life of capital assets used in Cytokinetics, Incorporated operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CYTK is equal to -33.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $25.934 million for Cytokinetics, Incorporated - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 54.888 million for Cytokinetics, Incorporated is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Cytokinetics, Incorporated at the current share price and the inputted number of shares is $0.6 billion.

RELATED COMPANIES Price Int.Val. Rating
AMGN Amgen Inc. 169.92 157.83  hold
VYGR Voyager Therap 24.48 0.32  str.sell
BIIB Biogen Inc. 230.87 418.24  buy
ACOR Acorda Therape 11.53 1.03  str.sell
IONS Ionis Pharmace 67.78 11.37  str.sell
PTCT PTC Therapeuti 39.96 2.84  str.sell

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.